OOSB yields 12.05% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, OOSB + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OOSB + PFE for your $10,000?
OOSB provides exposure to the S&P 500 and Bitcoin. The fund aims for long-term capital appreciation by using leverage through US-listed futures, pooled investment vehicles, and collateral. The fund targets 100% notional exposure for the returns of each component or an aggregate of 200%. The strategy seeks to magnify exposure so that every $1 investment is $1 exposure each to the S&P 500 and Bitcoin. The fund does not invest directly in Bitcoin but uses Bitcoin price reflected in the next or second-to-next expiring futures contract. In the case of other Bitcoin-linked investments, value is calculated by the average. Through a wholly owned Cayman Islands subsidiary, the fund invests in futures, ETPs with similar exposure, equities, and cash and cash equivalents. The actively managed ETF has full discretion to adjust the portfolio at any given time, while maintaining its tax status. Therefore, tracking deviation may be greater than the performance of the S&P 500 or Bitcoin.
Full OOSB Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.